Search tips
Search criteria 


Logo of neuroscibullNeuroscience Bulletin
Neurosci Bull. 2008 April; 24(2): 105.
Published online 2008 May 22. doi:  10.1007/s12264-008-0105-7
PMCID: PMC5552509

Language: English | Chinese

Alzheimer’s disease: epidemiology, genetics, and beyond



Alzheimer’s disease (AD) is an increasing epidemic threatening public health. Both men and women are susceptible to the disease although women are at a slightly higher risk. The prevalence of AD rises exponentially in elderly people from 1% at age of 65 to approximately 40%–50% by the age of 95. While the cause of the disease has not been fully understood, genetics plays a role in the onset of the disease. Mutations in three genes (APP, PSEN1, and PSEN2) have been found to cause AD and APOE4 allele increases the risk of the disease. As human genomic research progresses, more genes have been identified and linked with AD. Genetic screening tests for persons at high risk of AD are currently available and may help them as well as their families better prepare for a later life with AD.

Keywords: Alzheimer’s disease, amyloid precursor protein, presenilin, APOE


阿尔茨海默氏病是一种不断增长的威胁公众健康的流行疾患. 男女两性均对此病易感, 以女性稍甚. 该病患病率在老年人群中呈指数上升, 65 岁时患病率约1%, 至95 岁时达到40%–50%. 尽맜病因尚未被完全了解, 遗传因素已被确认在其发病中扮演重要角色. 发生在三个基因(APP, PSEN1, PSEN2)中的突变可导致该病, 而APOE4等位基因与患病的危险增加有关. 随着人类基因组研究的进展, 可能会有更多与该病相关的基因被发现. 目前, 应用遗传筛选测试, 可以帮助阿尔茨海默氏病的高危人群更好地准备和应对未来可能发生的疾病.

关键词: 阿尔茨海默氏病, β-淀粉样前体蛋白, 早老素, 载脂蛋白


[1] Helmer C., Joly P., Letenneur L., Commenges D., Dartigues J.F. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol. 2001;154:642–648. doi: 10.1093/aje/154.7.642. [PubMed] [Cross Ref]
[2] Aronson M.K., Ooi W.L., Geva D.L., Masur D., Blau A., Frishman W. Dementia: agedependent incidence, prevalence, and mortality in the old. Arch Intern Med. 1991;151:989–992. doi: 10.1001/archinte.151.5.989. [PubMed] [Cross Ref]
[3] Pinsky L.E., Burke W., Bird T.D. Why should primary care physicians know about the genetics of dementia? West J Med. 2001;175:412–416. doi: 10.1136/ewjm.175.6.412. [PMC free article] [PubMed] [Cross Ref]
[4] Ernst R.L., Hay J.W. The U.S. Economic and Social Costs of Alzheimer’s Disease Revisited. Am J Public Health. 1994;84:1261–1264. [PubMed]
[5] Koppel R. Alzheimer’s Disease: The Costs to U.S. Businesses in 2002. Washington, D.C.: Alzheimer’s Association; 2002.
[6] Joachim C.L., Morris J.H., Selkoe D.J. Clinically diagnosed Alzheimer’s disease: autopsy results in 150 cases. Ann Neurol. 1988;24:50–56. doi: 10.1002/ana.410240110. [PubMed] [Cross Ref]
[7] Mayeux R., Saunders A.M., Shea S., Mirra S., Evans D., Roses A.D., et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease. N Engl J Med. 1998;338:506–511. doi: 10.1056/NEJM199802193380804. [PubMed] [Cross Ref]
[8] Clark C.M., Ewbank D., Lee V.-Y., Trojanowski J.Q. Molecular pathology of Alzheimer’s disease: neuronal cytoskeletal abnormalities. In: Growdon J.H., Rossor M.N., editors. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth-Heinemann; 1998. pp. 285–304.
[9] Hutton M., Perez-Tur J., Hardy J. Genetics of Alzheimer’s disease. Essays Biochem. 1998;33:117–131. [PubMed]
[10] Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer Disease in the U.S. Population: Prevalence Estimates Using the 2000 Census. Arch Neurol. 2003;60:1119–1122. doi: 10.1001/archneur.60.8.1119. [PubMed] [Cross Ref]
[11] Nussbaum R.L., Ellis C.E. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003;348:1356–1364. doi: 10.1056/NEJM2003ra020003. [PubMed] [Cross Ref]
[12] Farrer L.A., O’sullivan D.M., Cupples L.A., Growdon J.H., Myers R.H. Assessment of genetic risk for Alzheimer’s disease among first-degree relatives. Ann Neurol. 1989;25:485–493. doi: 10.1002/ana.410250511. [PubMed] [Cross Ref]
[13] Silverman J.M., Li G., Zaccario M.L., Smith C.J., Schmeidler J., Mohs R.C., et al. Patterns of risk in first-degree relatives of patients with Alzheimer’s disease. Arch Gen Psychiatry. 1994;51:577–586. [PubMed]
[14] Rocchi A., Pellegrini S., Siciliano G., Murri L. Causative and susceptibility genes for Alzheimer’s disease: a review. Brain Res Bull. 2003;61:1–24. doi: 10.1016/S0361-9230(03)00067-4. [PubMed] [Cross Ref]
[15] Blacker D., Wilcox M.A., Laird N.M., Rodes L., Horvath S.M., Go R.C., et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998;19:357–360. doi: 10.1038/1243. [PubMed] [Cross Ref]
[16] Dodel R.C., Du Y., Bales K.R., Gao F., Eastwood B., Glazier B., et al. Alpha2 macroglobulin and the risk of Alzheimer’s disease. Neurology. 2000;54:438–442. [PubMed]
[17] Gibson A.M., Singleton A.B., Smith G., Woodward R., McKeith I.G., Perry R.H., et al. Lack of association of the alpha2-macroglobulin locus on chromosome 12 in AD. Neurology. 2000;54:433–438. [PubMed]
[18] Depboylu C., Lohmuller F., Du Y., Riemenschneider M., Kurz A., Gasser T., et al. Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer’s disease. Neurosci Lett. 2006;400:187–190. doi: 10.1016/j.neulet.2006.01.040. [PubMed] [Cross Ref]
[19] Reiman E.M., Webster J.A., Myers A.J., Hardy J., Dunckley T., Zismann V.L., et al. GAB2 alleles modify Alzheimer’s risk in APOE varepsilon4 carriers. Neuron. 2007;54:713–720. doi: 10.1016/j.neuron.2007.05.022. [PMC free article] [PubMed] [Cross Ref]
[20] Li Y.J., Oliveira S.A., Xu P., Martin E.R., Stenger J.E., Scherzer C.R., et al. Glutathione S-transferase omega-1 modifiesage-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003;12:3259–3267. doi: 10.1093/hmg/ddg357. [PubMed] [Cross Ref]
[21] Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168–177. doi: 10.1038/ng1943. [PMC free article] [PubMed] [Cross Ref]
[22] Campion D., Flaman J.M., Brice A., Hannequin D., Dubois B., Martin C., et al. Mutations of the presenilin I gene in families with early-onset Alzheimer’s disease. Hum Mol Genet. 1995;4:2373–2377. doi: 10.1093/hmg/4.12.2373. [PubMed] [Cross Ref]
[23] Sherrington R., Froelich S., Sorbi S., Campion D., Chi H., Rogaeva E.A., et al. Alzheimer’s disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet. 1996;5:985–988. doi: 10.1093/hmg/5.7.985. [PubMed] [Cross Ref]
[24] Janssen J.C., Beck J.A., Campbell T.A., Dickinson A., Fox N.C., Harvey R.J., et al. Early onset familial Alzheimer’s disease: Mutation frequency in 31 families. Neurology. 2003;60:235–239. [PubMed]
[25] Raux G., Guyant-Marechal L., Martin C., Bou J., Penet C., Brice A., et al. Molecular diagnosis of autosomal dominant early onset Alzheimer’s disease: an update. J Med Genet. 2005;42:793–795. doi: 10.1136/jmg.2005.033456. [PMC free article] [PubMed] [Cross Ref]
[26] Rocca W.A., Hofman A., Brayne C., Breteler M.M., Clarke M., Copeland J.R., et al. Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol. 1991;30:381–390. doi: 10.1002/ana.410300310. [PubMed] [Cross Ref]
[27] Campion D., Dumanchin C., Hannequin D., Dubois B., Belliard S., Puel M., et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:664–670. doi: 10.1086/302553. [PubMed] [Cross Ref]
[28] Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–923. doi: 10.1126/science.8346443. [PubMed] [Cross Ref]
[29] Jarvik G., Larson E.B., Goddard K., Schellenberg G.D., Wijsman E.M. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am J Hum Genet. 1996;58:191–200. [PubMed]
[30] D’Introno A., Solfrizzi V., Colacicco A.M., Capurso C., Amodio M., Todarello O., et al. Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer’s disease. Neurobiol Aging. 2006;27:1537–1553. doi: 10.1016/j.neurobiolaging.2005.09.020. [PubMed] [Cross Ref]
[31] Grupe A., Li Y., Rowland C., Nowotny P., Hinrichs A.L., Smemo S., et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet. 2006;78:78–88. doi: 10.1086/498851. [PubMed] [Cross Ref]
[32] Riemenschneider M., Konta L., Friedrich P., Schwarz S., Taddei K., Neff F., et al. A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer’s disease. Hum Mol Genet. 2006;15:2446–2456. doi: 10.1093/hmg/ddl167. [PubMed] [Cross Ref]
[33] Scott W.K., Hauser E.R., Schmechel D.E., Welsh-Bohmer K.A., Small G.W., Roses A.D., et al. Ordered-subsets linkage analysis detects novel Alzheimer disease Loci on chromosomes 2q34 and 15q22. Am J Hum Genet. 2003;73:1041–1051. doi: 10.1086/379083. [PubMed] [Cross Ref]
[34] Li Y., Grupe A., Rowland C., Nowotny P., Kauwe J.S., Smemo S., et al. DAPK1 variants are associated with Alzheimer’s disease and allele-specific expression. Hum Mol Genet. 2006;15:2560–2568. doi: 10.1093/hmg/ddl178. [PubMed] [Cross Ref]
[35] Wijsman E.M., Daw E.W., Yu C.E., Payami H., Steinbart E.J., Nochlin D., et al. Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2. Am J Hum Genet. 2004;75:398–409. doi: 10.1086/423393. [PubMed] [Cross Ref]
[36] Rademakers R., Cruts M., Sleegers K., Dermaut B., Theuns J., Aulchenko Y., et al. Linkage and association studies identify a novel locus for Alzheimer disease at 7q36 in a Dutch population-based sample. Am J Hum Genet. 2005;77:643–652. doi: 10.1086/491749. [PubMed] [Cross Ref]
[37] Bertram L., Hiltunen M., Parkinson M., Ingelsson M., Lange C., Ramasamy K., et al. Family-based association between Alzheimer’s disease and variants in UBQLN1. N Engl J Med. 2005;352:884–894. doi: 10.1056/NEJMoa042765. [PubMed] [Cross Ref]
[38] Bensemain F., Chapuis J., Tian J., Shi J., Thaker U., Lendon C., et al. Association study of the Ubiquilin gene with Alzheimer’s disease. Neurobiol Dis. 2006;22:691–693. doi: 10.1016/j.nbd.2006.01.007. [PubMed] [Cross Ref]
[39] Kamboh M.I., Minster R.L., Feingold E., DeKosky S.T. Genetic association of ubiquilin with Alzheimer’s disease and related quantitative measures. Mol Psychiatry. 2006;11:273–279. doi: 10.1038/ [PubMed] [Cross Ref]
[40] Smemo S., Nowotny P., Hinrichs A.L., Kauwe J.S., Cherny S., Erickson K., et al. Ubiquilin 1 polymorphisms are not associated with lateonset Alzheimer’s disease. Ann Neurol. 2006;59:21–26. doi: 10.1002/ana.20673. [PubMed] [Cross Ref]
[41] Liu F., Arias-Vasquez A., Sleegers K., Aulchnko Y.S., Kayser M., Sanchex-Juan P., et al. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet. 2007;81:17–31. doi: 10.1086/518720. [PubMed] [Cross Ref]
[42] Raiha I., Kaprio J., Koskenvuo M., Rajala T., Sourander L. Environmental differences in twin pairs discordant for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1998;65:785–787. doi: 10.1136/jnnp.65.5.785. [PMC free article] [PubMed] [Cross Ref]
[43] Pedersen N.L., Gatz M., Berg S., Johansson B. How heritable is Alzheimer’s disease late in life? Findings from Swedish twins. Ann Neurol. 2004;55:180–185. doi: 10.1002/ana.10999. [PubMed] [Cross Ref]
[44] Gatz M., Reynolds C.A., Fratiglioni L., Johansson B., Mortimer J.A., Berg S., et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168–174. doi: 10.1001/archpsyc.63.2.168. [PubMed] [Cross Ref]
[45] Pedersen N.L., Posner S.F., Gatz M. Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins. Am J Med Genet. 2001;105:724–728. doi: 10.1002/ajmg.1608. [PubMed] [Cross Ref]
[46] Borenstein A.R., Copenhaver C.I., Mortimer J.A. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:63–72. doi: 10.1097/01.wad.0000201854.62116.d7. [PubMed] [Cross Ref]
[47] Breitner J.C. APOE genotyping and Alzheimer’s disease. Lancet. 1996;347:1184–1185. doi: 10.1016/S0140-6736(96)90642-X. [PubMed] [Cross Ref]
[48] Breitner J.C., Wyse B.W., Anthony J.C., Welsh-Bohmer K.A., Steffens D.C., Norton M.C., et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 1999;53:321–331. [PubMed]

Articles from Neuroscience Bulletin are provided here courtesy of Springer